Navigation Links
Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases

A partnership between Kent State University, Summa Health System and IC-MedTech Inc. has yielded an innovative liquid crystal technology that offers the promise of new drugs which may more effectively manage cancer and other diseases.

The American Cancer Society estimates that nearly 1.5 million new cases of cancer will be diagnosed this year. This crisis has caused the National Cancer Institute to establish a goal of eliminating suffering and death due to cancer by the year 2015.

Kent State University, Summa Health System and IC-MedTech Inc. have taken steps toward that goal. Their collaborative efforts have yielded an innovative liquid crystal technology that offers the promise of new drugs which may more effectively manage cancer and other diseases.

Dr. Chun-che Tsai, Kent State professor of chemistry; Dr. Jim Jamison, manager of Urology, Obstetrics and Gynecology Core Basic Research Laboratory for Summa Health System; and Mr. Tom Miller, president of IC-MedTech Inc., a California-based biotechnology company, have developed a new paradigm in drug discovery based on the pharmacologic properties of liquid crystals called Liquid Crystal Pharmaceuticals or LCPs.

Recently, the team gathered at Kent State Universitys Office of Technology Transfer to file applications for two new patents: one for a new LCP-based anti-tumor drug called Tolecine and another for a formulation that combines Tolecine and another LCP, Apatone®.

The path-breaking discoveries of Dr. Tsai and his colleagues offer compelling proof of the value of university research and the enormous good that can come from collaborations between universities and the private sector, says Kent State President Lester A. Lefton. As Kent State researchers tackle cancer and a host of other real-world ills and issues, they are bringing their leading-edge knowledge and creativity to our students and playing a significant role in economic development.

Though best known for their use in laptops, televisions and cell phones, liquid crystals also include families of organic substances that are essential for all life called lyotropic liquid crystals. Examples of lyotropic liquid crystals include DNA, proteins and cholesterol. LCPs are a unique class of lyotropic liquid crystals that represent novel drug candidates for the treatment of a wide range of diseases.

Mother nature is the ultimate chemist, says Tsai. Although we use creative and sophisticated computer modeling techniques to screen for our candidate compounds, Im always amazed at how nature puts it all together.

The most recent research involving LCPs has yielded a new investigational anti-tumor drug called Tolecine, a compound that also has antiviral and antibacterial applications. Created by Tsai, it has been shown to be even more effective than the current standard of care for herpes.

The teams second patent application involves a formulation that combines Tolecine and another LCP, Apatone®, which attacks cancer cells via multiple pathways to offer improved efficacy. Apatone® has been successfully tested in more than 30 human tumor cell lines at Summa and in a Phase I/IIa clinical trial, which demonstrated a delaying effect in the progression of end-stage cancer patients. In addition, the FDA granted Apatone® orphan-drug status for the treatment of metastatic, or locally advanced, inoperable bladder cancer in August 2007.

Unlike other chemotherapy drugs, TolecineTM and Apatone® have low toxicity and do not target dividing cells. Instead, they are activated by inflammation that occurs in and around tumor cells, sparing healthy cells. We want to kill cancer cells specifically without killing surrounding tissues, says Jamison.

Innovative, low-toxicity drugs such as Tolecine and Apatone® provide new hope in the battle against cancer and other diseases in the next few years. Research on LCPs provides a solid scientific foundation for generations of new drugs, says Miller. Adds Tsai: LCPs are an untapped frontier from which many new, exciting treatments are now emerging.


Contact: Melissa Edler
Kent State University

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. NYU researchers simulate molecular biological clock
5. Researchers reveal the infectious impact of salmon farms on wild salmon
6. Researchers identify target for cancer drugs
7. Vital step in cellular migration described by UCSD medical researchers
8. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
9. UCSD researchers maintain stem cells without contaminated animal feeder layers
10. Researchers discover molecule that causes secondary stroke
11. Researchers find missing genes of ancient organism
Post Your Comments:
(Date:9/30/2015)... , Sept. 30, 2015  With nearly 300,000 Americans ... of new SCIs estimated to reach 12,500 annually, the ... California Resource Services for Independent Living (SCRS-IL) is ... California opening doors to independence ... programs and services, notably assistive technology services and education. ...
(Date:9/29/2015)... 29, 2015 News facts: ... also saving energy , Minimized design shrinks PC ... Active Mode and embedded Fujitsu PalmSecure authentication enable enterprises ... Fujitsu today shows that good things come in small ... to its enterprise desktop and mobile portfolio. Featuring workplace ...
(Date:9/28/2015)... YORK , Sept. 28, 2015  The ... respiration rate and body temperature, is an essential ... can be indicators of deterioration in a patient,s ... hospital, vital signs are typically taken during routine ... hours. If a patient deteriorates between these observation ...
Breaking Biology News(10 mins):
(Date:10/12/2015)... This report covers the global cell expansion ... applications, end-user markets and geographic segmentation. Forecasts are provided ... cell expansion market generated revenue of roughly $8.5 billion ... $9.7 billion in 2015 and $22.0 billion by 2020, ... from 2015 to 2020. This report provides: ...
(Date:10/12/2015)... Oct. 12, 2015  Patara Pharma, a clinical-stage ... inflammatory diseases and conditions, today announced the closing ... financing. Concurrent with the close of its sale ... Loan and Security Agreement with Silicon Valley Bank ... million. Patara will use the funds from the ...
(Date:10/12/2015)... ... October 12, 2015 , ... NeuMedics Inc., is a specialty biopharmaceutical company focused ... safely and chronically be administered as an eye drop, announced today it has been ... Clinic and taking place October 25th to October 28th at The Cleveland Clinic, Cleveland, ...
(Date:10/9/2015)... ANNAPOLIS, Md. , Oct. 9, 2015 ... entered into the Congressional Record her statement recognizing the ... celebrated October 11-17. IPAW is sponsored by the ... companies, and is designed to:   , Raise ... contributions of plasma donors in saving and improving lives ...
Breaking Biology Technology: